The Effect of High-Dose Vitamin D₃on Soluble P-Selectin and hs-CRP Level in Patients With Venous Thromboembolism

Abstract

High plasma level of P-selectin is associated with the development of venous thromboembolism (VTE). Furthermore, supplementation of vitamin D could decrease thrombotic events. Hence, this study was designed to examine whether the administration of vitamin D can influence the plasma level of P-selectin in patients with VTE. In the randomized controlled trial, 60 patients with confirmed acute deep vein thrombosis and/or pulmonary embolism (PE) were randomized into the intervention (n = 20) and control (n = 40) groups. The intervention arm was given an intramuscular single dose of 300 000 IU vitamin D3 Plasma level of 25-hydroxy vitamin D, P-selectin, and high-sensitive C-reactive protein (hs-CRP) was measured at baseline and 4 weeks after. The plasma level of P-selectin (95% confidence interval = -5.99 to -1.63, P = .022) and hs-CRP (P = .024) significantly declined in vitamin D-treated group, while only hs-CRP was significantly decreased in the control group (P = .011). However, the magnitude of these reductions was not statistically significant. This study could not support the potential benefit of the high-dose vitamin D on plasma level of P-selectin and hs-CRP in patients with VTE.

Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Pilot Randomized Clinical Trial

“…Furthermore, based on our previous studies, in our center the rate of vitamin D deficiency was reported as about 60%–65%. Therefore, we can assume a homogeneous level of vitamin D in our population …”

The Effect of Treatment of Vitamin D Deficiency on the Level of P‐Selectin and hs‐CRP in Patients With Thromboembolism: A Pilot Randomized Clinical Trial

“…The second study was a prospective randomized clinical trial in which we examined for the first time the effect of an intramuscular single dose of 300,000 IU vitamin D among 20 patients in the intervention group and 40 patients in the control group during a 1‐month period. Results indicated that vitamin D supplementation was not able to significantly reduce hs‐CRP or P‐selectin . However, this study included some limitations.…”

Pathogenic and Therapeutic Role of Vitamin D in Antiphospholipid Syndrome Patients

“…Results of recent trials assessing the effects of VitD supplementation on the risk of thromboembolism were inconclusive [62][63][64]. In the Multiple Environmental and Genetic Assessment (MEGA) case-control study which included 2506 patients with venous thrombosis, thrombotic risk was 37% lower in those supplemented with various vitamins including VitD [62].…”

“…However, in a large cohort of postmenopausal women (n=36282) from the Women's Health Initiative, daily supplementation with calcium and VitD failed to reduce the overall risk of thromboembolism [63]. Even when high doses (300,000 IU) of VitD were given intramuscularly, in a small group of patients with proven deep vein thrombosis and pulmonary embolism, observed reduction in plasma concentrations of P-selectin and high-sensitive Creactive protein (hs-CRP) did not reached statistical significance [64]. Additional information could be expected from the ongoing Vitamin D and OmegA-3 Trial (VITAL) and that is why the results of this investigation are eagerly awaited [65].…”